I don't usually post entire articles because of copywright laws, but here's the VASO article.
Mayo Clinic Physicians Confirm Positive Early Results With Enhanced External
Counterpulsation
BusinessWire, Tuesday, February 29, 2000 at 16:47
WESTBURY, NY--(BUSINESS WIRE)--Feb. 29, 2000--Vasomedical, Inc. (NASDAQ:VASO)
announced today that the Mayo Clinic, one of the most respected medical facilities in the world, has
reported further on initial results with enhanced external counterpulsation (EECP(R)) therapy. Their
positive experience was recently published as an interview in the Rochester Post-Bulletin and
confirms several case studies reported at the AHA in November.
Gregory Barsness, M.D., Medical Director for the EECP therapy program at Mayo reported,
"Of the 21 patients who've tried the therapy since Mayo started using it a year ago, 20 of them have
had positive results, some have improved dramatically. We are cautiously optimistic about the
therapy, ...we have had dramatic responses, so we're enthusiastic and we're actively pursuing it."
EECP therapy is a noninvasive outpatient treatment for the angina (chest pain) which often
accompanies coronary artery disease. The therapy, which is covered by Medicare, is relatively new to
the Mayo Clinic, but is in use at over 100 centers across the country.
Dr. Barsness further indicated that Mayo and other medical centers are studying EECP
therapy to determine why the treatment works in so many patients. He pointed out that heart disease
is a leading killer of both men and women; many heart disease patients do not qualify for common
treatment methods and EECP therapy could turn out to be a big help for these patients.
Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting
external counterpulsation systems based on the company's proprietary technology. EECP(R) is a
registered trademark for Vasomedical's enhanced external counterpulsation system. This system is
now in use at major medical centers, including the Mayo Clinic, the Ochsner Foundation Hospital and
the Miami Heart Institute, as well as medical centers affiliated with Columbia University, the University
of Pittsburgh, the University of California San Diego, the University of California San Francisco, and
the University of Virginia. The company provides hospitals, clinics and private practices EECP(R)
equipment, treatment guidance and a staff training and maintenance program to ensure optimal
patient outcomes.
Except for historical information contained in this release, the matters discussed are forward
looking statements that involve risks and uncertainties. When used in this release, words such as
"anticipate," "believe," "estimate," "expect" and "intend" and similar expressions, as they relate to the
Company or its management, identify forward-looking statements. Such forward-looking statements
are based on the beliefs of the Company's management, as well as assumptions made by and
information currently available to the Company's management. Among the factors that could cause
actual results to differ materially are the following: the effect of business and economic conditions; the
impact of competitive products and pricing; capacity and supply constraints or difficulties; product
development, commercialization or technological difficulties; the regulatory and trade environment; and
the risk factors reported from time to time in the Company's SEC reports. The Company undertakes
no obligation to revise any forward-looking statements as a result of future events or developments. |
